Evaluation of analgesia following Bupivacaine use in spine surgeries

Evaluation of postoperative analgesia following wound infiltration with Bupivacaine 0.25 solution after posterior lumbar spine surgeries

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210213050348N2

Enrollment

Registered

2021-09-01

Start date

2021-09-12

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spine degenerative damage. Other intervertebral disc degeneration, thoracolumbar region

Interventions

Intervention 1: Control group: Bupivacaine won't be injected into these patients. Intervention 2: Intervention group one: Bupivacaine. 30 cc of 0.25% Bupivacaine solution will be infiltrated into the

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over 18 years old whom are cases of degenerative damage to spine and undergo lumbar spine surgery.

Exclusion criteria

Exclusion criteria: No consent for being in this study. Addiction to opioids. Any contraindications for drug infiltration. Any history indicative of allergic reaction to the drugs used in this study. Chronic pain syndromes. History of seizure.

Design outcomes

Primary

Measure	Time frame
Visual Analogue Scale (VAS)score for surgical site pain. Timepoint: 6, 12 and 24 hours after surgery. Method of measurement: By asking the patient to point out his/her pain degree on the VAS chart.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Kamangar

Alborz University of Medical Sciences

dr_mkamangar@yahoo.com+98 26 3255 5000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026